Summary of Use during Lactation

No information is available on the clinical use of tezepelumab during breastfeeding. Because tezepelumab is a large protein molecule with a molecular weight of 147,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] An international consensus panel concluded that if the patient is in agreement, and the risks and benefits have been discussed, asthma biologics can be initiated or continued while breastfeeding.[3] Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[4]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Omalizumab

References

1.

Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003 [CrossRef]

2.

Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3. [PubMed: 33956488]

3.

Naftel J, Jackson DJ, Coleman M, et al. An international consensus on the use of asthma biologics in pregnancy. Lancet Respir Med 2024. [PubMed: 39216499]

4.

Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol 2023;22:350-66. [PubMed: 36931808]

Substance Name

Tezepelumab

CAS Registry Number

1572943-04-4

Drug Class

Breast Feeding

Lactation

Milk, Human

Anti-Allergic Agents

Anti-Asthmatic Agents

Antibodies, Monoclonal, Humanized